Search

BioMarin Pharmaceutical Inc

Закрыт

СекторЗдравоохранение

60.19 2.82

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

57.37

Макс.

58.79

Ключевые показатели

By Trading Economics

Доход

-34M

106M

Продажи

-108M

766M

P/E

Средняя по отрасли

41.234

56.269

Прибыль на акцию

0.76

Рентабельность продаж

13.773

Сотрудники

3,221

EBITDA

177M

173M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+47.48% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

679M

11B

Предыдущая цена открытия

57.37

Предыдущая цена закрытия

60.19

Новостные настроения

By Acuity

34%

66%

106 / 342 Рейтинг в Healthcare

BioMarin Pharmaceutical Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 июл. 2026 г., 20:06 UTC

Biomarin Pharmaceutical shares are lower today, continuing a decline since Thursday. No specific news was identified to explain the trading activity.

2 июл. 2026 г., 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1 июл. 2026 г., 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

30 июн. 2026 г., 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

29 июн. 2026 г., 23:21 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, retracing from earlier gains amid mixed U.S. equity performance and broader inflation concerns.

26 июн. 2026 г., 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 июн. 2026 г., 23:31 UTC

Biomarin Pharmaceutical shares declined in after-market trading, despite remaining above the 20-day moving average and near the upper end of its one-month range.

24 июн. 2026 г., 19:41 UTC

Biomarin Pharmaceutical Inc is gaining Wednesday, supported by strong momentum in the Biotechnology sub-sector, despite an earlier decline in the session.

23 июн. 2026 г., 23:56 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. Broader market sentiment is affected by declines in Asian markets amid tech sector concerns.

22 июн. 2026 г., 23:56 UTC

Biomarin Pharmaceutical shares showed little change in after-market trading. The stock remains within the middle of its one-month trading range.

19 июн. 2026 г., 00:01 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market hours, recovering from earlier lows and reflecting strong performance since Thursday's close.

18 июн. 2026 г., 23:21 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close despite earlier fluctuations in the session.

17 июн. 2026 г., 20:08 UTC

Event

Biomarin Pharmaceutical is trading lower amid broader market declines, despite presenting new data on VOXZOGO® and BMN 333 at the ENDO 2026 conference.

16 июн. 2026 г., 23:41 UTC

Event

Biomarin Pharmaceutical presented new data on investigational therapies at the Endocrine Society Annual Meeting. Shares showed little change during after-market hours.

15 июн. 2026 г., 13:26 UTC

Biomarin Pharmaceutical Inc is trading higher in pre-market hours, reflecting positive momentum amid a broader upward trend in Asian markets, including a surge in the Nikkei Index.

13 июн. 2026 г., 00:01 UTC

Biomarin Pharmaceutical Inc shares declined in after-market trading, retracing from earlier gains while remaining above the 20-day moving average. No specific news was identified.

12 июн. 2026 г., 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

11 июн. 2026 г., 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, reaching an early session low. Broader economic news includes an unexpected rise in initial jobless claims.

10 июн. 2026 г., 20:03 UTC

Biomarin Pharmaceutical shares are lower today, reflecting broader market trends amid volatility. The stock peaked earlier in the session before declining significantly.

9 июн. 2026 г., 20:03 UTC

Biomarin Pharmaceutical Inc shares are higher, reaching a session high and trading above its 20-day moving average. No specific news was identified for the move.

8 июн. 2026 г., 22:51 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, reflecting a notable decline despite a broader rebound in US stocks, particularly in the semiconductor sector.

5 июн. 2026 г., 20:07 UTC

Biomarin Pharmaceutical Inc shares are modestly higher, reflecting broader market gains amid robust job growth data. No specific company news was identified.

4 июн. 2026 г., 22:31 UTC

Biomarin Pharmaceutical Inc is trading lower in after-market hours amid a broader market decline and rising U.S. Treasury yields impacting biotechnology stocks.

3 июн. 2026 г., 20:06 UTC

Biomarin Pharmaceutical shares are higher amid broader market strength following a positive ADP Employment Report, which showed job growth exceeding expectations.

2 июн. 2026 г., 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, continuing a decline since Monday. The stock closed at its lowest point after an early high.

1 июн. 2026 г., 23:03 UTC

Biomarin Pharmaceutical shares declined in after-market trading, continuing a downward trend since Monday's close, despite remaining above the 20-day moving average.

29 мая 2026 г., 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid routine trading patterns.

28 мая 2026 г., 22:36 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting notable movement since Thursday's close amid broader market dynamics and economic data.

27 мая 2026 г., 19:41 UTC

Biomarin Pharmaceutical Inc shares are lower Wednesday, reversing recent gains. No specific news was identified to explain the decline since Tuesday's close.

26 мая 2026 г., 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from a recent trend of higher closes amid rising bond yields and no specific company news.

Сравнение c конкурентами

Изменение цены

BioMarin Pharmaceutical Inc Прогноз

Целевая цена

By TipRanks

47.48% рост

Прогноз на 12 месяцев

Средняя 87 USD  47.48%

Максимум 120 USD

Минимум 50 USD

Основано на мнении 20 аналитиков Wall Street, спрогнозировавших целевые цены для BioMarin Pharmaceutical Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

20 ratings

15

Покупка

5

Удержание

0

Продажа

Настроения

By Acuity

106 / 342Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat